

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Mark Jensen et al.	Group No.:	1625

U.S. Serial No.: 10/577,584

Filed: April 27, 2006 Examiner: Charanjit Aulakh

For: CCR-2 ANTAGONIST SALT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION

[37 CFR 1.321]

	I Mark P. Daniel	manidim a at
17 E	I, Mark R. Daniel Bailey Drive, Princeton, NJ 08540	, residing at
of th	ne assignee identified below, empowered to act on its behalf, pursporate Resolution No. 5, dated 04/22/2008.	suant to attached
pate	assignee, Merck & Co., Inc. t it is the assignee of the entire right, title and interest in the above ent application by virtue of an Assignment from the inventor(s) in ent application, which was	, certifies e-identified the aforesaid
X	recorded in the United States Patent & Trademark Office on Rec Frame(s) 0082 on 09/11/2007 ,	el(s) <u>019813</u>
	was forwarded for recording on, with a copy of t and assignment attached hereto, or	he recordation form
	is being concurrently forwarded for recording under separate coverecordation form and assignment attached hereto.	ver, with a copy of the
	aforesaid assignment establishes the ownership in the assignee o lication pursuant to 37 CFR 3.73(b).	f the above-identified
abov	undersigned has reviewed all of the evidentiary documents in the ve-identified patent application, and the undersigned certifies that ersigned's knowledge and belief, title is in the assignee named ab	t, to the best of the
abov	reby disclaim the terminal part of the statutory term of any patent ve-identified application, which would extend beyond the expirat utory term of:	
X	United States Patent No. <u>7,361,765</u> , or as presently shorte disclaimer,	ned by any terminal
	Any patent granted on application serial number	

and hereby agree that any patent so granted	on the above-identified application shall be
	that the legal title to said patent shall be the
same as the legal title to:	

United States Patent No. 7,361,7	65 ,
Any patent granted on application	on serial number,
this agreement to run with any patent binding upon the grantor, its successor	granted on the above-identified application and to be ors or assigns.
Petitioner does not disclaim any terms application prior to the expiration date	inal part of any patent granted on the above-identified e of the full statutory term of:
United States Patent No. <u>7,361,7</u> terminal disclaimer,	765, or as presently shortened by any
Any patent granted on application	on serial number,
is found invalid by a court of compete terminally disclaimed under 37 CFR certificate, is reissued, or is otherwise	ilure to pay a maintenance fee, is held unenforceable, ent jurisdiction, is statutorily disclaimed in whole or 1.321, has all claims canceled by a reexamination e terminated prior to expiration of its full statutory rminal disclaimer, except for the separation of legal
	arge Account No. 13-2755 the sum of \$130.00 is paper. A duplicate of this disclaimer is attached.
statements made on information and lestatements are made with the knowled are punishable by fine or imprisonme	ade herein of my own knowledge are true, and that all belief are believed to be true; and further, that these dge that willful false statements and the like so made ent, or both, under Section 1001 of Title 18 of the llful false statements may jeopardize the validity of this eon.
	mar And
	Disclaimant Mark R. Daniel
	Managing Counsel
In Duplicate Attachs.	Title Merck & Co., Inc. Patent Dept., RY60-30 P.O. Box 2000
Date: <u>07/22/2008</u>	Rahway, New Jersey 07065-0907 Telephone No. (732) 594- <u>6609</u>